Ustekinumab (SC injection)
Moderate to severe plaque psoriasis (NICE TA180)
NICE TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis
MHRA Drug Safety Update - Ustekinumab (Stelara): risk of exfoliative dermatitis
LMMG is adopting the local decisions made prior to April 2013.
Reason for decision: